A Prospective Randomized Trial of Esomeprazole- versus Pantoprazole-Based Triple Therapy for Helicobacter pylori Eradication-Reference-Cited by-同舟云学术

A Prospective Randomized Trial of Esomeprazole- versus Pantoprazole-Based Triple Therapy for Helicobacter pylori Eradication

Published:2005-11 Issue:11 Volume:100 Page:2387-2392
ISSN:0002-9270
Container-title:The American Journal of Gastroenterology
language:en
Short-container-title:Am J Gastroenterology

Author:

Hsu Ping-I,Lai Kwok-Hung,Lin Chiun-Ku,Chen Wen-Chi,Yu Hsien-Chung,Cheng Jin-Shiung,Tsay Feng-Woei,Wu Chung-Jen,Lo Ching-Chu,Tseng Hui-Hwa,Yamaoka Yoshio,Chen Jin-Liang,Lo Gin-Ho

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Gastroenterology,Hepatology

Reference32 articles.

1. Clinical Expressions of Helicobacter pylori Infection

2. Natural history and epidemiology ofHelicobacter pyloriinfection

3. Helicobacter pyloriInfection and the Development of Gastric Cancer

4. Risk factors for ulcer development in patients with non-ulcer dyspepsia: a prospective two year follow up study of 209 patients

5. The Interleukin-1 RN Polymorphism and Helicobacter pylori Infection in the Development of Duodenal Ulcer

Cited by 55 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Independent Risk Factors Predicting Eradication Failure of Hybrid Therapy for the First-Line Treatment of Helicobacter pylori Infection;Microorganisms;2023-12-19

2. Alcohol increases treatment failure for Helicobacter pylori eradication in Asian populations;BMC Gastroenterology;2023-10-25

3. Effects of Helicobacter pylori treatment on the incidences of autoimmune diseases and inflammatory bowel disease in patients with diabetes mellitus;PLOS ONE;2022-05-23

4. Eradication Rates for Esomeprazole and Lansoprazole-Based 7-Day Non-Bismuth Concomitant Quadruple Therapy for First-Line Anti-Helicobacter pylori Treatment in Real World Clinical Practice;Infection and Drug Resistance;2021-03

5. High Body Mass Index Is Correlated with the Success of Vonoprazan-Based Second-Line Therapy for Helicobacter Pylori Infection;The Tohoku Journal of Experimental Medicine;2021